Exosomes are extracellular vesicles (EVs) of endosomal origin that range in size between 30 and 150 nanometers. Exosomes are secreted by a wide range of cells, since virtually all living cells utilize exosome-mediated communication. Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells. [Read more…]
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform
LONDON, UK and BOCA RATON, FL, — INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity that set up the world’s first stem cell register and is now driving forward cell therapy advancements, announced the signing of an amended and restated Material Transfer and License Agreement. This expanded collaboration secures the long-term provision of high-quality umbilical cord tissue to power INmune Bio’s CORDStrom™ platform, the industry’s most advanced Mesenchymal Stromal Cell (MSC) technology designed to deliver consistent, scalable, and “off-the-shelf” cellular therapies which are suitable for supply in UK, EU and US, as well as other global regions. [Read more…]
Hopstem’s iPSC-derived neural progenitor cell injection earns FDA RMAT designation for chronic stroke
HOUSTON, June 03, 2026 – Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its proprietary iPSC-derived human forebrain neural progenitor cell injection, hNPC01. The candidate has displayed potential for treating persistent motor dysfunction due to basal ganglia ischemic stroke in phase I clinical study. [Read more…]
FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison
-
Site will serve as company’s new headquarters and expands capacity and capabilities for induced pluripotent stem cell development and manufacturing
-
New facility is part of a $200 million investment by Fujifilm in expanding research product and cell therapy manufacturing capabilities in the U.S. to support the growing global market
Madison, WI, May 19, 2026 – FUJIFILM Cellular Dynamics Inc., a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs), celebrated the opening of its new headquarters and iPSC development and manufacturing facility in its Madison home. The new site is expected to quadruple the capacity for the company’s iPSC-based research products and services manufacturing footprint and expand capabilities across FUJIFILM Cellular Dynamics’ research product portfolio. [Read more…]
Factor Bioscience to Reveal Two Novel iPSC-derived MSC (iMSC) Programs at ASGCT 2026
- Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs
- Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors (FACT-112), as well as recent advances in Factor’s RNA-based cell reprogramming technologies
- Factor to reveal two novel iPSC-derived mesenchymal stem cell (iMSC) programs: Hypoimmune iMSCs for muscular dystrophy and HTRA1-expressing iMSCs for neurodegenerative disorders
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 337
- Next Page »